Journal of Advanced Pharmaceutical Technology & Research

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 11  |  Issue : 2  |  Page : 59--63

The optimization method for synthesis of technetium-99m-luteolin as radiotracer in the development of cancer drugs from flavonoid


Danni Ramdhani1, Maula Eka Sriyani2, S Fairuz Nabila1 
1 Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Padjadjaran University, Sumedang, West Java, Indonesia
2 Applied Nuclear Science and Technology Center (PSTNT), National Atomic Energy Agency (BATAN), Bandung, West Java, Indonesia

Correspondence Address:
Mr. Danni Ramdhani
Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Padjadjaran University, Sumedang 45363, West Java
Indonesia

The aim of this study is to find the optimum conditions of labeling luteolin flavonoid compounds with technetium-99m (99mTc) to meet the purity requirements stated in the United States Pharmacopeia. This compound is expected to be a potential radiotracer compound for diagnosing cancer. The optimization method in labeling luteolin with technetium determines the parameters such as pH, SnCl2.2H2O, genistein concentration, and incubation time. Optimization results of Technetium-99m-luteolin labeling obtained optimum pH conditions 8, the amount of SnCl2.2H2O as a reducing agent 60 μL, the optimum amount of luteolin 6 mg/ml, and the optimum incubation time is 30 min. This optimum condition obtained a99mTc-Luteolin radiochemical purity yield of 94.15%. The radiochemical purity percentage of the99mTc-Luteolin compound has fulfilled the requirements listed at United States Pharmacopeia, which is ≥90%.


How to cite this article:
Ramdhani D, Sriyani ME, Nabila S F. The optimization method for synthesis of technetium-99m-luteolin as radiotracer in the development of cancer drugs from flavonoid.J Adv Pharm Technol Res 2020;11:59-63


How to cite this URL:
Ramdhani D, Sriyani ME, Nabila S F. The optimization method for synthesis of technetium-99m-luteolin as radiotracer in the development of cancer drugs from flavonoid. J Adv Pharm Technol Res [serial online] 2020 [cited 2021 Sep 23 ];11:59-63
Available from: https://www.japtr.org/article.asp?issn=2231-4040;year=2020;volume=11;issue=2;spage=59;epage=63;aulast=Ramdhani;type=0